Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- IATCIIndependent statistical analysis of IV Iron for the Anemia of Traumatic Critical Illness: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01180894).
- iATTENDIndependent statistical analysis of The Improving ATTENDance to Cardiac Rehabilitation Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03646760).
- IBPSIndependent statistical analysis of Using Intradialytic Blood Pressure Slopes to Guide Ultrafiltration: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03303391).
- Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02956382).
- Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03207555).
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01849263).
- Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- IBSCIIndependent statistical analysis of The Relationship Between Irisin and Bone Health in Individuals With Spinal Cord Injury: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back Pain: Complete Statistical AnalysisIndependent statistical analysis of Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03068897).
- Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study: Complete Statistical AnalysisIndependent statistical analysis of Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01229449).
- ICEIndependent statistical analysis of Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00220740).
- ICECANIndependent statistical analysis of Interstitial Cystitis: Examination of the Central Autonomic Network: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03008382).
- ICGIndependent statistical analysis of Low Dose ICG for Biliary Tract and Tumor Imaging: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04942665).
- iCLAS™ for Persistent Atrial Fibrillation: Complete Statistical AnalysisIndependent statistical analysis of iCLAS™ for Persistent Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04061603).
- ICONIndependent statistical analysis of Inpatient Clinical Trial of NAC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03581084).
- ICONAIndependent statistical analysis of A Phase 2b Study of Icosabutate in Fatty Liver Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04052516).
- ICONIC-TOTALIndependent statistical analysis of A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet):…
- ICT-HCTIndependent statistical analysis of Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Ictal and Interictal Inflammatory Markers in Migraine: Complete Statistical AnalysisIndependent statistical analysis of Ictal and Interictal Inflammatory Markers in Migraine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01138150).
- ID11-56Independent statistical analysis of An Evaluation of Marketed Contact Lens Disinfectant Systems on Eyelid Tissues: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- iDCLIndependent statistical analysis of The International Diabetes Closed Loop (iDCL) Trial: Protocol 1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02985866).
- IDEAL-PCIIndependent statistical analysis of Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- iDEAt2Independent statistical analysis of A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently…
- Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Identification and Treatment of Cervical Abnormalities in Perú Through Integration of Pocket Colposcopy and Telemedicine: Complete Statistical AnalysisIndependent statistical analysis of Identification and Treatment of Cervical Abnormalities in Perú Through Integration of Pocket Colposcopy and Telemedicine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- IDENTIFYIndependent statistical analysis of Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Identifying and Treating Depression in Hemodialysis Patients: Complete Statistical AnalysisIndependent statistical analysis of Identifying and Treating Depression in Hemodialysis Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03390933).
- IDENTITY-2Independent statistical analysis of Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients: Complete Statistical AnalysisIndependent statistical analysis of IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02854059).
- IDMPCIndependent statistical analysis of Improving Depression Management: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05050227).
- IDTIndependent statistical analysis of Individual Differences in Drug Response: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03809546).
- IELSG30Independent statistical analysis of Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis:…
- IGF-1 and Bone Loss in Women With Anorexia Nervosa: Complete Statistical AnalysisIndependent statistical analysis of IGF-1 and Bone Loss in Women With Anorexia Nervosa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01406444).
- iGlarLixi vs IDegAsp in Chinese Participants After OAD(s): Complete Statistical AnalysisIndependent statistical analysis of iGlarLixi vs IDegAsp in Chinese Participants After OAD(s): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05413369).
- IGNAZIndependent statistical analysis of Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- IHAIndependent statistical analysis of Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia: Complete Statistical AnalysisIndependent statistical analysis of IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00524342).
- IL-17 Neutrophils in CF Lung Inflammation: Complete Statistical AnalysisIndependent statistical analysis of IL-17 Neutrophils in CF Lung Inflammation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02025829).
- IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA: Complete Statistical AnalysisIndependent statistical analysis of IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- ILIADEIndependent statistical analysis of Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than…
- Illness Management and Recovery for Veterans With Severe Mental Illness: Complete Statistical AnalysisIndependent statistical analysis of Illness Management and Recovery for Veterans With Severe Mental Illness: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00515671).
- ILMARI2Independent statistical analysis of Impact of Adding a Limitation Section in Abstract of Systematic Review: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability: Complete Statistical AnalysisIndependent statistical analysis of Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…